Staging of small cell lung cancer VA staging divides small cell lung cancer into two stages: limited disease and extensive disease. The material point of limited stage is that the tumor is confined to one side of the chest cavity, including the presence of supraclavicular or anterior oblique muscle lymph node metastasis and ipsilateral pleovaginal effusion. For limited stage small cell lung cancer, further clinical staging should be performed according to TNM stage so that patients with different stages can be more accurately treated individually and optimally. Extensive stage is characterized by lesions beyond the confined stage. Staging of lung cancer includes clinical staging, surgical pathological staging and re-treatment staging The staging based on all clinical information collected before treatment is called clinical staging, prefixed with Co and identified as cTNM-cStage After surgical treatment, the information of disease is derived from pathological examination of resected specimens, which is more accurate, and the staging made at this time is called surgical pathological staging, prefixed with p. In the multidisciplinary comprehensive treatment of lung cancer, before transferring to the second discipline after the first discipline treatment, another staging is performed to help estimate the efficacy of the previous stage and formulate the next treatment plan and provide reference for the final efficacy evaluation, which is called retreatment staging, with r as the prefix. Molecular staging of lung cancer can be explored in hospitals with conditions Molecular staging refers to the application of molecular biology techniques to detect micro-metastases in intrathoracic lymph nodes, peripheral blood and bone marrow specimens that cannot be detected by conventional methods to determine the stage of lung cancer, with m as prefix. The combination of molecular staging with clinical staging, surgical pathological staging and re-treatment staging can more accurately reflect the early and late stages of patients’ disease and more individually formulate treatment plans. However, the current method is not yet mature.